HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. PK results support once a...
Continuously optimize user experience, Baijiayun's live and on-demand products complete autumn upgrade
BEIJING, Nov. 22, 2024 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, recently announced it has completed autumn upgrade. Driven by both technological development and market...